Dana Investment Advisors Inc. Has $8.38 Million Stock Position in Zoetis Inc. $ZTS

Dana Investment Advisors Inc. reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 10.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,282 shares of the company’s stock after selling 6,511 shares during the period. Dana Investment Advisors Inc.’s holdings in Zoetis were worth $8,382,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of ZTS. Halbert Hargrove Global Advisors LLC lifted its position in shares of Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares in the last quarter. NewSquare Capital LLC grew its position in Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares in the last quarter. Financial Consulate Inc. acquired a new position in Zoetis in the 3rd quarter valued at approximately $39,000. SJS Investment Consulting Inc. increased its stake in Zoetis by 1,606.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after buying an additional 257 shares during the period. Finally, TruNorth Capital Management LLC purchased a new stake in Zoetis in the 3rd quarter worth approximately $42,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 2.3%

Shares of ZTS stock opened at $125.77 on Tuesday. The stock’s 50 day simple moving average is $125.50 and its 200 day simple moving average is $134.48. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $177.00. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The company has a market capitalization of $53.09 billion, a price-to-earnings ratio of 20.89, a PEG ratio of 1.97 and a beta of 0.96.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter last year, the company posted $1.40 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio is 35.22%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ZTS shares. HSBC set a $140.00 price target on shares of Zoetis in a report on Wednesday, December 10th. Piper Sandler restated a “neutral” rating and issued a $135.00 target price (down previously from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. JPMorgan Chase & Co. cut their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Bank of America increased their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.